Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors

Human Vaccines

Volumn 7, Issue 6, 2011, Pages 639-645

  Hara, Hiroto ^a   Hironaka, Takashi ^a   Inoue, Makoto ^a   Iida, Akihiro ^a   Shu, Tsugumine ^a   Hasegawa, Mamoru ^a   Nagai, Yoshiyuki ^b   Falsey, Ann R ^c   Kamali, Anatoli ^d   Anzala, Omu ^e   Sanders, Eduard J ^f,g   Karita, Etienne ^h   Mwananyanda, Lawrence ⁱ   Vasan, Sandhya ^j   Lombardo, Angela ^k   Parks, Christopher L ^k   Sayeed, Eddy ^k   Krebs, Marietta ^k   Cormier, Emmanuel ^l   Ackland, James ^k   Price, Matthew A ^k   Excler, Jean Louis ^k   more..

^a DNAVEC Corporation   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

^c ROCHESTER GENERAL HOSPITAL   (United States)

^d UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h Rwanda Zambia HIV Research Group   (Rwanda)

ⁱ Rwanda Zambia HIV Research Group   (Zambia)

^j AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^k INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

AIDS vaccine; HIV; Neutralizing antibody; Pre existing immunity; Sendai virus; Vector

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MALE; QUANTITATIVE ANALYSIS; SENDAI VIRUS; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; AFRICA; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; EUROPE; FEMALE; GENETIC VECTORS; HUMANS; JAPAN; MALE; MIDDLE AGED; PARAINFLUENZA VIRUS 1, HUMAN; SENDAI VIRUS; UNITED STATES;

EID: 79959334662     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.6.15408     Document Type: Article

References (61)

1. UNAIDS. AIDS epidemic update: December 2010.
2. Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008; 320:760-4. (Pubitemid 351929619)
3. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med 2004; 10:769-71. (Pubitemid 39070840)
4. Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP, Jamieson BD, et al. Estimating the Benefit of an HIV-1 Vaccine That Reduces Viral Load Set Point. J Infect Dis 2007; 4:546-50. (Pubitemid 46214397)
5. Berkley SF, Koff WC. Scientific and policy challenges to development of an AIDS vaccine. Lancet 2007; 370:94-101. (Pubitemid 47017469)
6. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
7. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009; 361:2209-20.
8. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009; 83:6508-21.
9. Robert-Guroff M. replicating and non-replicating viral vectors for vaccine development. Current Opinion in Biotechnology 2007; 18:1-11.
10. Koff WC, Parks CL, Berkhout B, Ackland J, Noble S, Gust ID. Replicating viral vectors as HIV vaccines: Summary Report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference, July 22, 2007. Biologicals 2008; 36:277-86.
11. Conzelmann KK. Reverse genetics of mononegavirales. Curr Top Microbiol Immunol 2004; 283:1-41. (Pubitemid 38667556)
12. Takimoto T, Bousse T, Portner A. Molecular cloning and expression of human parainfluenza virus type 1 L gene. Virus Res 2000; 70:45-53.
13. Smith FS, Portner A, Leggiadro RJ, Turner EV, Hurwitz JL. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology 1994; 205:453-61. (Pubitemid 24371686)
14. Dave VP, Allan JE, Slobod KS, Smith FS, Ryan KW, Takimoto T, et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology 1994; 199:376-83. (Pubitemid 24168975)
15. Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine 2008; 26:3480-8.
16. Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3 and RSV. Vaccine 2009; 27:1848-57.
17. Hurwitz JL. Development of Recombinant Sendai Virus Vaccines for Prevention of Human Parainfluenza and Respiratory Syncytial Virus Infections. Pediatr Infect Dis J 2008; 27:126-8.
18. Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol 2004; 78:6043-7. (Pubitemid 38661692)
19. Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, et al. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol 2005; 18:255-66. (Pubitemid 41106005)
20. Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine 2007; 25:8782-93. (Pubitemid 350199594)
21. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, Kano M, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199:1709-18. (Pubitemid 38822004)
22. + cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques. J Virol 2007; 81:11640-9.
23. + Effector T Cells Responding to a Secreted Human Immunodeficiency Virus Type 1 Envelope Glycoprotein. J Virol 2007; 8:12535-42.
24. + T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques. J Virol 2009; 83:9339-46.
25. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90:966-73. (Pubitemid 34633862)
26. Huang J, Inoue M, Hasegawa M, Tomihara K, Tanaka T, Chen J, et al. Sendai viral vector mediated angiopoietin-1 gene transfer for experimental ischemic limb disease. Angiogenesis 2009; 12:243-9.
27. Kinoh H, Inoue M, Komaru A, Ueda Y, Hasegawa M, Yonemitsu Y. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Ther 2009; 16:392-403.
28. Ueda Y, Hasegawa M, Yonemistu Y. Sendai virus for cancer immunotherapy. In: Hicks BW, Ed. Methods in Molecular Biology, Viral Applications of Green Fluorescent Protein. New York, NY: Humana Press 2009; 299-308.
29. Inoue H, Iga M, Nabeta H, Yokoo T, Suehiro Y, Okano S, Inoue M, et al. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Sci 2008; 99:2315-26.
30. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85:348-62.
31. Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010; 7:11-4.
32. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769-81. (Pubitemid 351706778)
33. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009; 25:103-14.
34. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003; 77:799-803. (Pubitemid 36005022)
35. Cook MK, Chanock RM. In vivo antigenic studies of parainfluenza viruses. Am J Hyg 1963; 77:150-9.
36. Tai FH, Chiu S, Ma CC. Sero-epidemiologic studies of Sendai virus infection on Taiwan. J Formos Med Assoc 1967; 66:312-8.
37. Sakaguchi T, Kiyotani K, Sakaki M, Fujii Y, Yoshida T. A field isolate of Sendai virus: its high virulence to mice and genetic divergence form prototype strains. Arch Virol 1994; 135:159-64. (Pubitemid 2059512)
38. Ryan-Poirier KA, Kawaoka Y. Distinct glycoprotein inhibitors of influenza A virus in different animal sera. J Virol 1991; 65:389-95.
39. Benne CA, Kroon FP, Harmsen M, Tavares L, Kraaijeveld CA, De Jong JC. Comparison of neutralizing and hemagglutination-inhibiting antibody responses to influenza A virus vaccination of human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1998; 5:114-7. (Pubitemid 28062957)
40. Lennette EH, Schmidt NJ, Eds. Hemagglutination-inhibition test, Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, Washington, DC: American Public Health Association 1979; 5.
41. Fidgen KJ. The action of Vibrio cholerae and Corynebacterium diphtheriae neuraminidases on the Sendai virus receptor of human erythrocytes. J Gen Microbiol 1975; 89:48-56.
42. Komada H, Kusagawa S, Orvell C, Tsurudome M, Nishio M, Bando H, et al. Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by using monoclonal antibodies. J Gen Virol 1992; 73:875-84.
43. Lyn D, Gill DS, Scroggs RA, Portner A. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants. J Gen Virol 1991; 72:983-7.
44. Olson LC, Lexomboon U, Sithisarn P, Noyes HE. The etiology of respiratory tract infections in a tropical country. Am J Epidemiol 1973; 97:34-43.
45. Fry AM, Curns AT, Harbour K, Hutwagner L, Holman RC, Anderson LJ. Seasonal trends of human parainfluenza viral infections: United States 1990-2004. Clin Infect Dis 2006; 43:1016-22.
46. Slobod KS, Shenep JL, Luján-Zilbermann J, Allison K, Brown B, Scroggs RA, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004; 22:3182-6. (Pubitemid 39037223)
47. Kato M, Igarashi H, Takeda A, Sasaki Y, Nakamura H, Kano M, et al. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine 2005; 23:3166-73.
48. Moriya C, Horiba S, Inoue M, Iida A, Hara H, Shu T, et al. Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques. Biochem Biophys Res Commun 2008; 371:850-4.
49. Brandler S, Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 2008; 31:271-91. (Pubitemid 351315119)
50. Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M, et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009; 27:3299-305.
51. Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, et al. Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses 2010; 2:435-67.
52. Radosevic K, Rodriguez A, Lemckert A, Goudsmit J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev Vaccines 2009; 8:577-92.
53. Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009; 27:4468-74.
54. Excler JL, Parks CL, Ackland J, Rees H, Gust ID, Koff WC. Replicating viral vectors as HIV vaccines: Summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 2010; 38:511-21.
55. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 2009; 183:6883-92.
56. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:3548.
57. Matano T, Matsuoka S, Ishii H, Inoue M, Iida A, Hara H, et al. Intranasal Sendai viral vector administration is more immunogenic than intramuscular in the presence of anti-vector antibodies. AIDS Res Hum Retroviruses 2010; 26:164.
58. Yoshizaki M, Hironaka T, Iwasaki H, Ban H, Tokusumi Y, Iida A, et al. Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. J Gene Med 2006; 8:1151-9. (Pubitemid 44480406)
59. Hasan MK, Kato A, Shioda T, Sakai Y, Yu D, Nagai Y. Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J Gen Virol 1997; 78:2813-20. (Pubitemid 27480820)
60. st Sieroter Milan 1979; 57:700-6.
61. Hierholzer JC, Suggs MT, Hall EC. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl Microbiol 1969; 18:824-33.